Updates are available Correction dated 2019-05-30
Click to view Correction: https://doi.org/10.1038/s41467-019-10456-x
-
Authors
Caswell-Jin, Jennifer L. https://orcid.org/0000-0002-5711-8355
McNamara, Katherine https://orcid.org/0000-0002-3717-6494
Reiter, Johannes G. https://orcid.org/0000-0002-0170-7353
Sun, Ruping https://orcid.org/0000-0003-3702-9483
Hu, Zheng
Ma, Zhicheng
Ding, Jie
Suarez, Carlos J.
Tilk, Susanne
Raghavendra, Akshara
Forte, Victoria
Chin, Suet-Feung https://orcid.org/0000-0001-5697-1082
Bardwell, Helen
Provenzano, Elena
Caldas, Carlos https://orcid.org/0000-0003-3547-1489
Lang, Julie https://orcid.org/0000-0002-7534-6124
West, Robert
Tripathy, Debu https://orcid.org/0000-0002-5711-2404
Press, Michael F.
Curtis, Christina https://orcid.org/0000-0003-0166-3802
- License Information
-
More Information
Article History
Received: 24 August 2018
Accepted: 18 January 2019
First Online: 8 February 2019
Change Date: 30 May 2019
Change Type: Correction
Change Details: The original version of this Article omitted from the Author Contributions statement that ‘R.S. and J.G.R contributed equally to this work.’ This has been corrected in both the PDF and HTML versions of the Article.
Competing interests
: J.L. reports research funds from ANGLE Parsortix and is a member of the speaker bureau of Genomic Health. M.F.P. holds consulting or advisory role with honoraria at Karyopharm Therapeutics, Puma Biotechnology, Biocartis, Eli Lilly & Company, Novartis Pharmaceuticals, F. Hoffmann La-Roche Ltd. C. Caldas is a Scientific Advisor to Astrazeneca-iMed and has received research funding from Astrazeneca, Servier, Genentech/Roche. M.F.P. has received research grants to his institution from: Cepheid, Eli Lilly & Company, Novartis Pharmaceuticals, F. Hoffmann La-Roche Ltd. C. Curtis is a Scientific Advisory Board member and shareholder of GRAIL and consultant for GRAIL and Genentech. The remaining authors declare no competing interests.
